SPEED OF LIFE

– Building a strong and sustainable Life science sector – together

 

Company representatives from the prosperous Life science industry, will share their journey, success strategies and examples concerning entrepreneurship. Business leaders, researchers, marketers, economists, business developers and other experts jointly describe the environment their companies operate in, what drives them and what challenges they face.
Listen, be inspired, learn and take the insights to your company and gain value today!

New episodes will be published every second week from May 2021. In addition, to give you even more insight in the everyday life of the entrepreneurs, our LinkedIn account will be ”hijacked” by the company presented, during the week of promotion. Stay up to date by following STUNS Life science on LinkedIn.

This podcast is sponsored through the project BIO-X Accelerate led by STUNS Life science with the goal of promoting a sustainable growth of the Life science industry in East Middle Sweden. The project is funded by European Regional Development Fund (ERDF), Region Uppsala and STUNS Life Science.

We look forward to sharing value with you. 

Podcast series

Celluminova AB

Near-instant detection of live stem cells

– The Biomarker Gliostem® will help neurosurgeons distinguish between healthy and cancerous tissue during brain tumor surgery

Celluminova specializes in developing new tools for stem cell research, including cancer stem cells. The patented biomarker GlioStem is intended for the detection and visualization of stem cell-like cells in brain tumors. Today, there are no products on the market that target stem cell-like cells in these tumors. The goal for GlioStem is to be used during surgery to completely remove tumor tissue and thereby lead to increased patient survival and quality of life.

Read more about Celluminova

Gradientech AB

Precision medicine for a sustainable world

Gradientech is a Swedish diagnostics company dedicated to supporting the modern microbiology lab with state-of-the-art solutions that facilitate the testing of time-critical sepsis samples.

Gradientech is currently developing the in vitro diagnostic QuickMIC® system, a new platform for ultra-rapid testing of antibiotic resistance. The system is expected to become the most rapid solution for determining the appropriate antibiotic treatment of sepsis patients. Rapid testing of antibiotic resistance is vital for increasing sepsis patient survival, reducing healthcare costs, and lowering the spread of antibiotic resistance.

Read more about Gradientech

PU Sensor AB

PU sensor enables prevention of pressure ulcers

PU sensor has developed a method for evaluating a patient’s physiological condition regarding blood flow at pressure and thereby anticipate the risk of pressure ulcer and prevent it from appearing.

Pressure ulcer (bedsore) is a both painful and dangerous but unfortunately common medical injury. Among health care related injuries, pressure ulcers are one of the most burdensome both economically and when it comes to human suffering, OECD reports. Pressure ulcers arise in all age groups and all over the world. Cost increase with ulcer severity because the time to heal is longer and the incidence of complication is higher in more severe cases. The cost of treating pressure ulcer is likely to increase in the future as the population ages.

Read more about PU Sensor

Ilya Pharma AB

Ilya Pharma is developing next-generation immunotherapies to treat wounds in skin and mucosa

The ILP-technology is based on deploying chemokines, which until now have been regarded too unstable to be suitable as therapeutics. Ilya Pharma has overcome this problem by letting live lactic acid bacteria produce and deliver the human therapeutic chemokines on site in wounds in skin or e.g in the intestine acting like small bioreactors. In addition to the documented biologic and clinical effect on accelerating the healing and recovery, it is a very cost efficient system to deliver drugs, compared to cell therapies and other traditional biologics.

Read more about Ilya Pharma

Astrego AB

Providing the antibiotic resistance profile at the point of care

The increase of antibiotic resistance is a global threat to human health. It is due to over- and miss-use of antibiotics, as a result of that doctors currently need to prescribe antibiotics before they know the resistance profile of the bacteria.

Astrego’s technology provides such a resistance profile in 30 min and therfore allows prescription of effective,  non-broad spectrum, antibiotics at the point-of-care. Astrego’s first product targets urinary tract infection, which affects 100 milj women each year, and represents 15% of the antibiotic use in human medicine.

Read more at astrego.se

BioReperia AB

BioReperia’s revolutionary ZTX-Platform and related products

BioReperia helps every cancer patient to get the most effective treatment available, for their specific disease.

BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.

Our goal is to increase the speed and accuracy of preclinical drug development and clinical cancer treatment, enabling researchers and clinicians to select the drugs/drug candidates with the highest potential to succeed in less time.

Read more at bioreperia.com

Senzime AB

With the vision of a world without anesthesia related complications

With the vision to eliminate anesthesia related complications, we develop and commercialize systems powered by unique algorithms and sensors to monitor patient muscle function and electrical impulses, before, during and after surgery.

The company’s solution is called TetraGraph®, a medical device system that digitally and continuously measures the level of neuromuscular blockade in the patient. The system is based on EMG technology and more than 10 of the R&D from the Mayo clinic in the US.

Read more at senzime.com

Immuneed AB

A great team with a drive to become number one

Advanced therapies are increasingly being developed for patients in need, thereby putting pressure on the drug developers to produce qualified, effective, and safe matches. Immuneed combines our strong scientific knowledge with a versatile preclinical platform based on fresh, circulating human blood. Thereby, we provide our customers with a tailored solution in the early stage of development, enabling safe and effective drugs.

Read more at immuneed.com

Deversify AB

Everyone should understand their own health — meet Deversify

Deversify is a Swedish R&D company offering tech solutions in consumer health. We develop and commercialize mobile electronic devices and apps to monitor biomarkers for individualized health. Our products help people understand — and improve — their own health. Our mission is to act as a good force against today’s lifestyle diseases – such as obesity, diabetes, addictions, and cardiovascular disease.

Deversify operates in growing consumer health markets which today in Europe and US alone are valued at over USD 5 billion. Our first product, the ketone breathalyzer Acetrack®, measures if your body is burning fat and is currently sold to health-tech consumers. Deversify is here to help you understand your wellbeing holistically – inside and out, from ketones to ECG.

Read more at deversify.com

Stardots AB

A digital health platform for neurological diseases

Stardots develops a deep-tech Software-as-a-Medical-Device (SaMD) for Parkinson’s disease with the goal to increase quality of life and lower cost to society.

Parkinson’s disease is complex, non-curable and costly, and causes great amount of suffering to the patient and their relatives. Since there are no readily available bio-markers, care is often subjective, unequal and not optimized. Stardots digital health approach is to offer progressive markers by mathematical modelling of symptoms (e.g., tremor) and using these objective estimators to optimize current treatment (e.g., deep brain stimulation). Our unique algorithms are based on many years of R&D at Uppsala university and tested in pilot studies at Uppsala University Hospital, and we have strong indications that similar approaches could be valid for other neurological diseases.

Read more at stardots.se

 

Coming next:

 

Week 49 Special Episode 

New podcasts are published regularly. Follow us on LinkedIn to stay up to date
Picture: Logo of the European Regional Development Fund